Continuation of Evolution: Headliner Glargine U300

When the glargine U300 molecule was first developed, the target was the patients, who treated with high insulin dosage, due to its three times concentrated composition and gradual release compared to U100 formulation. The following studies have also showed that, with the use of U300 formulation compared to the use of U100 formulation, there were fewer nocturnal episodes of severe hypoglycemia, lower weight gain (-0.5 kg) and smaller difference between maximum and minimum glucose levels within the 24 hour period, which means less glucose variability.

Source: Medical Hypotheses - July 23, 2018 Category: Biomedical Science Authors: Utku Erdem Soyaltin, Ilg ın Yildirim Şimşir, Şevki Çetinkalp Source Type: research